Ontramab 150 mg Injection 7.2 ml

Ontramab 150 mg Injection 7.2 ml is an anti-cancer medicine used in the treatment of HER2-positive Breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. Cancer is a disease where the cells grow abnormally and divide uncontrollably. It can also be used when the cancer has spread to other parts of the body.

Ontramab 150 mg Injection 7.2 ml contains Trastuzumab as an active ingredient, which belongs to the class of monoclonal antibodies. It works by inhibiting the abnormal growth of cancer cells and, finally, causes the initiation of programmed cell death.

Ontramab 150 mg Injection 7.2 ml may cause certain side effects such as abdominal pain, chills, diarrhoea, fatigue, nausea, back pain, bone pain, edema, insomnia, fever, dizziness, headache, vomiting, cough, rash, and injection site reactions. If the side effects persist or bother you, please consult your doctor. Ontramab 150 mg Injection 7.2 ml will be administered by a trained doctor. Hence, do not self-administer.

Avoid taking it and inform your doctor if you are allergic to Ontramab 150 mg Injection 7.2 ml or its components. Inform your doctor if you have any cardiovascular conditions, lung problems, or liver/kidney disease, as it can cause adverse effects. Ontramab 150 mg Injection 7.2 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.

Ontramab 150 mg Injection 7.2 ml contains Trastuzumab, which is used for treating patients with HER2-positive breast cancer and HER2-positive metastatic gastroesophageal adenocarcinoma. This medicine works by inhibiting the excess production of a human epidermal growth factor receptor 2 (HER2) protein in the mammalian cells. This causes inhibition of the cancer cell growth and, finally, initiation of programmed cell death.

• Nausea
• Vomiting
• Diarrhoea
• Myalgia
• Bone pain
• Headache
• Fatigue
• Injection site reactions
• Pain at the site of injection
• Dizziness
• Edema
• Cough
• Rash
• Insomnia

Ontramab 150 mg Injection 7.2 ml should be avoided if you are allergic to it or any other components of this medicine. Inform your doctor if you have any lung problems, cardiovascular conditions or liver/kidney disease, as it can cause adverse effects. Ontramab 150 mg Injection 7.2 ml may cause left ventricular ejection fraction, cardiomyopathy, pulmonary toxicity, exacerbations of chemotherapy-induced neutropenia, and hypersensitivity reactions during the treatment. Hence, careful observation should be performed for any reactions in the patient. Ontramab 150 mg Injection 7.2 ml may cause embryo-fetal toxicity. Hence, if you are pregnant or planning to become pregnant, inform your doctor beforehand. Breastfeeding should be discontinued in nursing mothers during the treatment. Ontramab 150 mg Injection 7.2 ml is not recommended for use in children as the safety and efficacy are not established.

• ETANERCEPT
• NATALIZUMAB
• INDINAVIR
• EFAVIRENZ
• ATAZANAVIR
• GOLIMUMAB

• Avoid intercourse while on treatment with Ontramab 150 mg Injection 7.2 ml.
• Regular, complete blood count monitoring is advised during the treatment.
• All patients should be tested for HER2 test before starting the treatment regimen.
• Liver function tests (LFT) and pulmonary function tests (PFT) should be performed before starting the treatment and every 4 to 6 weeks during the treatment.
• Regular ECG and electrolytes should be monitored while taking the medicine.

• Meditation and yoga have been proven very effective in helping cancer patients maintain a healthy attitude and body.
• Eat more lean meats, healthy fats, fruits, vegetables, and whole-grain foods to give you more energy. 
• Stay hydrated by drinking plenty of water, as dehydration is often seen in cancers.
• Taking a stroll in the garden or spending 30 minutes of your time doing some light physical activity can be very useful. However, do not over-exert yourself if you feel too tired. 
• Avoid smoking and alcohol consumption.